Holen Sie sich die Stockscreener-App
4.7489
2.04%
0.0889
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat
Relay Therapeutics' SWOT analysis: stock poised for growth amid fierce competition - MSN
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8%Time to Sell? - MarketBeat
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate - Yahoo Finance
Relay Therapeutics’ (RLAY) Buy Rating Reiterated at HC Wainwright - Defense World
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Given "Buy" Rating at HC Wainwright - MarketBeat
Relay Therapeutics Highlights Progress at Healthcare Conference - TipRanks
Barclays PLC Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Barclays PLC Purchases 136,541 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws - MSN
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Relay Therapeutics stock hits 52-week low at $4 By Investing.com - Investing.com South Africa
Relay Therapeutics (NASDAQ:RLAY) Hits New 12-Month LowShould You Sell? - MarketBeat
Relay Therapeutics stock hits 52-week low at $4 - Investing.com India
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws (LLY:NYSE) - Seeking Alpha
Relay Therapeutics Chief Corporate Development Officer Peter Rahmer Sells 63% Of Holding - Simply Wall St
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 4.8%Should You Buy? - MarketBeat
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Relay Therapeutics officer sells shares worth $345,571 By Investing.com - Investing.com Australia
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells $73,763.20 in Stock - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 32,156 Shares - MarketBeat
Relay Therapeutics officer sells shares worth $345,571 - Investing.com India
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Grows Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics' chief corporate development officer sells $1,752 in stock - Investing.com India
Relay Therapeutics stock hits 52-week low at $4.11 amid market challenges - Investing.com Australia
Relay Therapeutics president sells shares for $2,877 By Investing.com - Investing.com Australia
Relay Therapeutics’ chief corporate development officer sells $1,752 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics' chief corporate development officer sells $1,752 in stock By Investing.com - Investing.com Australia
Relay Therapeutics president sells shares for $2,877 - Investing.com India
Relay Therapeutics chief legal officer sells $1,309 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics chief legal officer sells $1,309 in stock - Investing.com India
Thomas Catinazzo Sells 4,865 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock - MarketBeat
Relay Therapeutics CFO sells $21,490 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics CFO sells $21,490 in stock - Investing.com
1.67%
9.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):